ITGB6

Across TCGA pan-cancer cohorts, ITGB6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ITGB6 data layer compared with 23 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ITGB6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ITGB6 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where ITGB6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.264	0.519	.009	20	view →
CCRCC	OS	Tertile	IV	0.150	1.000	.036	12	view →
LSCC	DFS	Quartile	II,III,IV	0.442	0.866	.014	7	view →
COAD	DFS	Median	II,III,IV	1.000	0.925	.043	6	view →
LUAD	OS	Median	II,III,IV	0.429	0.911	.008	6	view →
UCEC	DFS	Median	All	1.000	0.936	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ITGB6–PDAC (DFS)

Open the PDAC breakdown →